EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Long‐term effectiveness and safety outcomes in adults with Fabry disease treated with agalsidase alfa: 20 years of data from the Fabry Outcome Survey

Derralynn A Hughes, Guillem Pintos-Morell, Christoph Kampmann, Christina Anagnostopoulou, Jaco Botha iD, Siddharth Jain, Kathleen Nicholls, Dau-Ming Niu, Ricardo Reisin, Michael L West, Jörn Schenk, Uma Ramaswami und 1 weitere

European Journal of Clinical Investigation · 2026-01 · 56 (1)

DOI: 10.1111/eci.70142 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Clinical Investigation, online erschienen am 06.11.2025. Verfasst von Derralynn A Hughes und 12 weiteren Autor:innen. Beteiligte Einrichtung: Royal Free London NHS Foundation Trust, University College London, London, UK. Hauptthemen laut MEDLINE: Fabry Disease, alpha-Galactosidase. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Development Center Americas, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We present the final report from the Fabry Outcome Survey (FOS) on long‐term effectiveness and safety of agalsidase alfa in adults (≥18 years old).

Methods

FOS was an international, multicentre, observational registry (NCT03289065), designed to enhance the understanding of Fabry disease and improve clinical management. Primary effectiveness endpoints were annualized change in estimated glomerular filtration rate (eGFR) and left ventricular mass index (LVMI), and time to and age at composite morbidity event (comprising renal, cardiac or stroke events) and death. Safety outcomes were also assessed.

Results

FOS included data for 1864 adults (female/male, n = 907/957) who received agalsidase alfa only for a median (minimum, maximum) of 6.0 (0, 21.6) years, and 1613 untreated adults (female/male, n = 1235/378). At baseline, mean (standard deviation [SD]) eGFR was 94.01 (27.60) mL/min/1.73 m 2 in treated adults; annualized changes in eGFR (slope [standard error; SE]) remained relatively stable in females and declined slightly in males (−1.07 [.12] vs. −2.17 [.12] mL/min/1.73 m 2 ). At baseline, mean (SD) LVMI was 58.25 (25.01) g/m 2.7 and LVMI (slope [SE]) remained stable (.34 [.16] vs. .38 [.15] g/m 2.7 /year in females and males, respectively). Time (median [95% confidence interval]) from treatment initiation to first composite event was longer for females than males (83.4 [65.7–98.0] vs. 56.3 [45.6–66.7] months); age (median [minimum, maximum]) at death was also higher for treated females than males (69.9 [32.5, 87.7] vs. 59.1 [26.2, 79.6] years). Agalsidase alfa was generally well tolerated.

Conclusions

This report further supports the long‐term effectiveness and safety of agalsidase alfa in adults with Fabry disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fabry Diseasealpha-GalactosidaseHumansMaleFemaleAdultMiddle AgedGlomerular Filtration RateTreatment OutcomeIsoenzymesRecombinant ProteinsAgedYoung AdultRegistriesHypertrophy, Left VentricularStrokeEnzyme Replacement Therapy

Stichwörter der Autor:innen

Fabry Outcome SurveyFabry diseaseagalsidase alfacardiacregistryrenal

Substanzen

agalsidase alfaalpha-GalactosidaseIsoenzymesRecombinant Proteins

Autor:innen und Institutionen

  • Royal Free London NHS Foundation Trust, University College London, London, UK.
  • Vall d'Hebron Research Institute, Barcelona, Spain.
  • Medical Consulting Committee, MPS-Lisosomales Association, Barcelona, Spain.
  • Johannes Gutenberg School of Medicine, University of Mainz, Mainz, Germany.
  • Takeda Pharmaceuticals International AG, Zurich, Switzerland.
  • Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.

ORCID-Profile: Jaco Botha

Förderung

  • Takeda Development Center Americas, Inc.

Zitieren

APA

Hughes, D. A., Pintos-Morell, G., Kampmann, C., Anagnostopoulou, C., Botha, J., Jain, S., Nicholls, K., Niu, D. M., Reisin, R., West, M. L., Schenk, J., Ramaswami, U., & Giugliani, R. (2026). Long‐term effectiveness and safety outcomes in adults with Fabry disease treated with agalsidase alfa: 20 years of data from the Fabry Outcome Survey. European Journal of Clinical Investigation, 56(1). https://doi.org/10.1111/eci.70142

Vancouver

Hughes DA, Pintos-Morell G, Kampmann C, Anagnostopoulou C, Botha J, Jain S, et al. Long‐term effectiveness and safety outcomes in adults with Fabry disease treated with agalsidase alfa: 20 years of data from the Fabry Outcome Survey. European Journal of Clinical Investigation. 2026;56(1). doi:10.1111/eci.70142

BibTeX
@article{Hughes2026,
  author = {Hughes, Derralynn A and Pintos-Morell, Guillem and Kampmann, Christoph and Anagnostopoulou, Christina and Botha, Jaco and Jain, Siddharth and Nicholls, Kathleen and Niu, Dau-Ming and Reisin, Ricardo and West, Michael L and Schenk, Jörn and Ramaswami, Uma and Giugliani, Roberto},
  title = {Long‐term effectiveness and safety outcomes in adults with Fabry disease treated with agalsidase alfa: 20 years of data from the Fabry Outcome Survey},
  journal = {European Journal of Clinical Investigation},
  year = {2026},
  volume = {56},
  number = {1},
  doi = {10.1111/eci.70142}
}
Kostenlos starten →